Hanguang Hu

Key Laboratory Of Cancer Prevention And Intervention
Hangzhou, 310009, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Updates of CSCO guidelines for colorectal cancer version 2026.

Updates of CSCO guidelines for colorectal cancer version 2026.

Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu

Published: June 01, 2026

Caveolae in cancer: mechanochemical signaling in tumor progression, immunity, and therapy.

Caveolae in cancer: mechanochemical signaling in tumor progression, immunity, and therapy.

Journal: Cell communication and signaling : CCS

Published: February 12, 2026

Efficacy of surufatinib in advanced Grade 3 neuroendocrine tumors: a real-world, national, multicenter study.

Efficacy of surufatinib in advanced Grade 3 neuroendocrine tumors: a real-world, national, multicenter study.

Journal: Therapeutic advances in medical oncology

Published: January 04, 2026

Updates of CSCO guidelines for colorectal cancer version 2025.

Updates of CSCO guidelines for colorectal cancer version 2025.

Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu

Published: April 16, 2025

Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p).

Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p).

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 07, 2025

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update.

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update.

Journal: Cancer communications (London, England)

Published: November 27, 2024

CSCO guidelines for colorectal cancer version 2024: Updates and discussions.

CSCO guidelines for colorectal cancer version 2024: Updates and discussions.

Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu

Published: May 07, 2024

CSCO guidelines for colorectal cancer version 2023: Updates and insights.

CSCO guidelines for colorectal cancer version 2023: Updates and insights.

Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu

Published: May 09, 2023

Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial.

Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial.

Journal: EClinicalMedicine

Published: April 11, 2023

Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study.

Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study.

Journal: BMC cancer

Published: March 07, 2023

Novel insights into the progression and prognosis of the calpain family members in hepatocellular carcinoma: a comprehensive integrated analysis.

Novel insights into the progression and prognosis of the calpain family members in hepatocellular carcinoma: a comprehensive integrated analysis.

Journal: Frontiers in molecular biosciences

Published: February 09, 2023

A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol.

A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol.

Journal: Technology in cancer research & treatment

Published: February 02, 2023

Showing 1-12 of 41

Last Updated: 09/26/2026